Vetoquinol (FRA:8JM) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vetoquinol Debt-to-Equity?

Vetoquinol's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €8.0 Mil. Vetoquinol's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €9.7 Mil. Vetoquinol's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €527.0 Mil. Vetoquinol's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vetoquinol's Debt-to-Equity or its related term are showing as below:

FRA:8JM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.34
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Vetoquinol was 0.34. The lowest was 0.02. And the median was 0.04.

FRA:8JM's Debt-to-Equity is ranked better than
88.77% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs FRA:8JM: 0.03

Vetoquinol Debt-to-Equity Historical Data

The historical data trend for Vetoquinol's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vetoquinol Debt-to-Equity Chart

Vetoquinol Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.34

0.04

0.03

Vetoquinol Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.04	0.04	0.03	0.03

Competitive Comparison of Vetoquinol's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vetoquinol's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vetoquinol's Debt-to-Equity falls into.

Vetoquinol Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vetoquinol's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.965	+	9.663)	/	527.013
	=	0.03

Vetoquinol's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.965	+	9.663)	/	527.013
	=	0.03

Vetoquinol (FRA:8JM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vetoquinol Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vetoquinol's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vetoquinol (FRA:8JM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vetoquinol SA (FRA:8JM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VETO:France

Address

Magny-Vernois, BP 189, Lure cedex, FRA, 70204

Website

http://www.vetoquinol.com

Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.

Vetoquinol (FRA:8JM) Headlines

No Headlines